The 6th Annual Maui Derm NP+PA Fall 2020 meeting will be held at the Gaylord Opryland Hotel in Nashville, Tennessee from September 28-October 1, 2020. The Fall meeting is part of our “On the Road” program that brings Maui Derm NP+PA to inspired locations throughout the U.S.

This four-day meeting will feature a one day “Special Pre-Conference Day” held on September 28, 2020 followed by our three day meeting.

The highly interactive sessions are designed to validate your current practice patterns while updating your skills in a variety of areas. Based on last year’s requests we have added a surgical workshop, dermatopathology session and a connective tissue disorder symposium.

You will learn some alternate ways to handle common problems and emerging methods to tackle those tough cases. Our world-class faculty have geared their presentations toward providing pearls you can put to use your first day back at work! Disease pathogenesis, differential diagnoses, therapeutic mechanisms of action, treatment algorithms and outcome measures are incorporated into case based discussions. Ample time for Q&A has been built into the program.

We encourage you to join us for what promises to be an exceptional educational opportunity and look forward to meeting you in Nashville, TN.

1. Review the pathogenesis of various dermatological conditions such as infectious diseases, psoriasis, psoriatic arthritis, acne vulgaris, rosacea, hidradenitis, contact dermatitis, atopic dermatitis, eczema, pruritus, actinic keratoses, melanoma and non-melanoma skin cancer, pediatric skin disorders, connective tissue disorders, granulomatous disorders of the skin, connective tissue diseases, hair and nail disorders, leg ulcers, oral lesions and life-threatening dermatoses such as TEN in order to accurately diagnose and improve upon the management of these conditions in patients
2. Cite the mechanisms of action of various drugs, including topical and systemic therapies, as well as immunomodulatory agents that are commonly prescribed by the nurse practitioner and physician assistant practicing in dermatology and identify patients in your practice for whom these therapies may be appropriate
3. Define appropriate outcome measures for the optimal follow-up of patients with dermatologic diseases as well as those receiving surgical and cosmetic procedures in order to set realistic expectations and maximize therapeutic outcomes
4. Describe potential adverse events, safety, tolerance and resistance issues that may be related to the use of various drugs and therapies prescribed by clinicians in dermatology as well as therapeutic modalities including: topical and systemic corticosteroids, newer biologic agents, including TNF antagonists, T-cell and B-cell targeted therapies, anti-IL-12/23 therapies, IL-23 & IL-17 antibodies, systemic and topical PDE4 inhibitors, JAK inhibitors, anti-IgE and anti-IL 4 receptor, systemic retinoids, methotrexate, cyclosporine, neurokinin-1 receptor antagonists, systemic and topical acne/rosacea therapies, systemic hidradenitis suppuritiva therapies, oral and topical antibiotics, antifungals, anti-viral therapies, wound healing agents, antihistamines, calcineurin inhibitors, topical skin lightening agents, sunscreens, topical and systemic retinoids, 5-fluorouracil, imiquimod, ingenol mebutate, diclofenac, photodynamic therapy, hedgehog pathway inhibitors, rituximab, BRAF/MEK inhibitors, CTLA-4 and PD-1/PDL-1 inhibitors, botulinum toxins, dermal filler agents including hyaluronic acid, collagen, polylactic acid, hydroxyappetite based fillers, and implement appropriate management strategies in order to reduce these adverse effects and optimize patient outcomes
5. Assess the data around emerging and novel therapeutics for a variety of dermatologic diseases and develop treatment algorithms and management strategies for the optimal use of these therapies
6. Identify scenarios that warrant discussion of benefit/risk and assessment of patient satisfaction

Please go to the website for the Registration Fees:

Pre-Conference Day  + Main Conference Registration

It is important that you choose the track most suitable to you. Any possible changes on-site will be based on the availability of space and printed materials, and may have a surcharge.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Advances in Cosmetic and Medical Dermatology. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this live activity for a maximum of 30.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.

Gaylord Opryland Hotel, 2800 Opryland Drive, Nashville, TN 37214

No faculty are available for this activity at this time.